



Department
of Health

Medicaid Managed Care Plan Updates

SARS-CoV-2, Poliovirus, and Monkeypox Virus

COVID-19 Vaccine Administration Code Update

The New York State (NYS) Department of Health (the Department) has activated the following CPT codes for the administration of the Pfizer-BioNTech primary vaccine series for children ages 6 months to 4 years of age effective as of the United States Food & Drug Administration's (FDA) Emergency Use Authorization (EUA) effective date 6/17/2022:

CPT Code	Manufacturer & COVID-19 Vaccine Administration CPT Code Short Description	Fee
0081A	Pfizer-BioNTech - ADM SARSCOV2 3MCG/0.2ML Trs-Sucr – 1 st dose	\$40.00
0082A	Pfizer-BioNTech - ADM SARSCOV2 3MCG/0.2ML Trs-Sucr – 2 nd dose	\$40.00
0083A	Pfizer-BioNTech - ADM SARSCOV2 3MCG/0.2ML Trs-Sucr – 3 rd dose	\$40.00

NYS Medicaid coverage and billing guidance for COVID-19 Vaccine administration is located at:
https://www.health.ny.gov/health_care/medicaid/covid19/guidance/billing_guidance.htm

COVID-19 Vaccine Administration Code Update

The Department has activated the following CPT codes for the administration of two Moderna primary vaccine series for children ages 6 months to 5 years of age and 6 to 11 years of age effective as of the FDA's EUA effective date 6/17/2022:

CPT Code	Manufacturer & COVID-19 Vaccine Administration CPT Code Short Description	Fee
0091A	Moderna - ADM SARSCOV2 50MCG/0.5ML (6yrs - 11yrs) - 1st dose	\$40.00
0092A	Moderna - ADM SARSCOV2 50MCG/0.5ML (6yrs - 11yrs) – 2nd dose	\$40.00
0093A	Moderna - ADM SARSCOV2 50MCG/0.5ML (6yrs - 11yrs) – 3rd Dose	\$40.00
0111A	Moderna - ADM SARSCOV2 25MCG/0.25ML (6mos-5yrs) – 1st Dose	\$40.00
0112A	Moderna - ADM SARSCOV2 25MCG/0.25ML (6mos-5yrs) – 2nd Dose	\$40.00
0113A	Moderna - ADM SARSCOV2 25MCG/0.25ML (6mos-5yrs) - 3rd Dose	\$40.00

NYS Medicaid coverage and billing guidance for COVID-19 Vaccine administration is located at:
https://www.health.ny.gov/health_care/medicaid/covid19/guidance/billing_guidance.htm

COVID-19 Vaccine Update – Novavax EUA revised

The FDA has amended the EUA for the Novavax vaccine for administration in individuals 12 years of age and older effective 8/22/2022 (originally authorized for 18 years of age and older effective 7/13/2022). The Department has activated the following CPT codes for the administration of the Novavax vaccine:

CPT Code	Manufacturer & COVID-19 Vaccine Administration CPT Code Short Description	Fee
0041A	Novavax - ADM SARSCOV2 VAC 5MCG/0.5ML - 1st Dose	\$40.00
0042A	Novavax - ADM SARSCOV2 VAC 5MCG/0.5ML – 2nd Dose	\$40.00

NYS Medicaid coverage and billing guidance for COVID-19 Vaccine administration is located at:
https://www.health.ny.gov/health_care/medicaid/covid19/guidance/billing_guidance.htm

COVID-19 Vaccine Administration Code Update: New Bivalent Vaccine Booster Codes

On August 31, 2022, [FDA amended the EUAs](#) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize [bivalent formulations of the vaccines](#) for use as a single booster dose at least two months following primary or booster vaccination.

The Department has activated the following CPT codes for the administration of the Pfizer-BioNTech (for ages 12 and older) and Moderna (ages 18 and older) bivalent vaccine booster doses effective as of the FDA's EUA effective date 8/31/2022:

CPT Code	Manufacturer & COVID-19 Vaccine Administration CPT Code Short Description	Fee
0124A	Pfizer-BioNTech – ADM SARS-CoV-2, bivalent, 30 mcg/0.3 mL – booster dose	\$40.00
0134A	Moderna - ADM SARS-CoV-2, bivalent, 50 mcg/0.5 mL – booster dose	\$40.00

NYS Medicaid coverage and billing guidance for COVID-19 Vaccine administration is located at: https://www.health.ny.gov/health_care/medicaid/covid19/guidance/billing_guidance.htm

COVID-19 Vaccine Administration Code Update

The Department has **deactivated** the following CPT codes for the administration of the Pfizer-BioNTech and Moderna monovalent vaccine booster doses effective as of 9/1/2022:

CPT Code	Manufacturer & COVID-19 Vaccine Administration CPT Code Short Description
0004A	Pfizer-BioNTech - ADM SARSCOV2 30MCG/0.3ML - Booster Dose
0054A	Pfizer-BioNTech - ADM SARSCOV2 30MCG TRS-SUCR - Booster Dose
0064A	Moderna - ADM SARSCOV2 50MCG/0.25ML - Booster Dose
0094A	Moderna - ADM SARSCOV2 50MCG/0.5ML - Booster Dose

The Department will continue to monitor the developments on COVID-19 vaccines and publish updates to the “NYS Medicaid Coverage Policy and Billing Guidance for the Administration of COVID-19 Vaccines” document located at:

https://www.health.ny.gov/health_care/medicaid/covid19/guidance/billing_guidance.htm

September 2022

Covid-19 Therapeutic – Bebtelovimab Commercially Available

Bebtelovimab, represented by CPT code Q0222, became commercially available the week of August 15th, 2022. Pharmacies and practitioners are now able to procure the product directly.

Pharmacies and practitioners **MAY NOT** seek reimbursement for bebtelovimab distributed at no cost by NYS from the United States Government (USG). Inventory distributed at no cost must be separated from any commercially purchased supply of bebtelovimab.

When the supply that was received at no cost is exhausted, providers may submit a claim for the acquisition cost of commercially acquired bebtelovimab.

NYS Medicaid billing guidance for COVID-19 Testing, Specimen Collection and Therapeutics is located at:

http://devweb.health.ny.gov/health_care/medicaid/covid19/guidance_for_specimen_collection.htm

Monkeypox Virus Update

On July 29, 2022, NYS Governor Kathy Hochul signed Executive Order No. 20, declaring a disaster emergency in NYS due to the ongoing spread of the monkeypox virus. On August 4, 2022, the Biden Administration declared a federal Public Health Emergency. On August 28, 2022, Governor Hochul signed Executive Order No. 20.1, waiving cost sharing, copayments, and/or coinsurance for monkeypox virus vaccine administration, lab testing, and initial diagnostic evaluations.

The Department has published two Medicaid Update articles:

- “*Updated Identification, Specimen Collection, Testing, Vaccine Administration, and Treatment for Suspected Cases of Orthopoxvirus/Monkeypox*” provides coverage and billing guidance for testing and vaccine administration located at:
https://www.health.ny.gov/health_care/medicaid/program/update/2022/no08_2022-07.htm#monkeypox
- “*Copayments Waived for Monkeypox Diagnostic Evaluations, Vaccine Administration, and Testing*” located at:
https://www.health.ny.gov/health_care/medicaid/program/update/2022/no09_2022-08.htm#copayments

September 2022

Polio Virus Update

The Department has published a Medicaid Update article in the August 2022 edition titled “*New York State Medicaid Polio Vaccine Coverage*” to remind providers NYS Medicaid provides coverage for the inactivated poliovirus vaccine (IPV) and the administration of IPV when administered to Medicaid FFS members and MMC enrollees. This article is located at:

https://www.health.ny.gov/health_care/medicaid/program/update/2022/no09_2022-08.htm#poliovaccine

IPV vaccine counseling is also covered for individuals under 19 years of age as part of the Early and Periodic Screening, Diagnostic, and Treatment Program. The March 2022 Medicaid Update article titled “*Early and Periodic Screening, Diagnostic, and Treatment Program Childhood Vaccine Counseling Coverage Benefit*” provides coverage and billing guidance and is located at:

https://www.health.ny.gov/health_care/medicaid/program/update/2022/no03_2022-03.htm#vaccinecounseling



Department
of Health

Thank You!

Questions?

Policy questions can be sent to:

FFSMedicaidPolicy@health.ny.gov